AVEO Pharmaceuticals, Inc.
(NASDAQ : AVEO)

( )
AVEO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
-0.11%358.111.2%$821.20m
AMGNAmgen Inc.
-0.54%191.761.2%$548.88m
CELGCelgene Corporation
-0.51%85.341.2%$519.45m
GILDGilead Sciences, Inc.
-0.09%77.050.9%$473.46m
VRTXVertex Pharmaceuticals Incorporated
-0.56%180.121.9%$315.55m
REGNRegeneron Pharmaceuticals, Inc.
0.48%367.742.6%$284.44m
ILMNIllumina, Inc.
0.59%309.103.5%$264.44m
SRPTSarepta Therapeutics, Inc.
0.14%135.5316.6%$232.12m
BLUEBluebird Bio, Inc.
-0.33%178.9515.7%$201.94m
ALXNAlexion Pharmaceuticals, Inc.
-0.41%135.092.0%$176.54m
NKTRNektar Therapeutics
2.51%49.085.6%$174.06m
EXASExact Sciences Corporation
1.30%67.6125.4%$158.76m
EXELExelixis, Inc.
0.05%21.346.4%$136.40m
BMRNBioMarin Pharmaceutical Inc.
0.18%102.874.4%$125.14m
AAgilent Technologies, Inc.
1.84%64.151.5%$122.61m

Company Profile

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380, and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.